Announced
Completed
Financials
Tags
Minority
Completed
Biotechnology
Venture Capital
United States
Private Equity
Friendly
biotechnology company
Private
Acquisition
Single Bidder
Cross Border
Synopsis
Flagship Pioneering led a $126m Series C round in Omega Therapeutics, a development-stage biotechnology company, with participation from Invus, Fidelity Management & Research Company, BlackRock, Cowen, Point72, Logos Capital and Mirae Asset Capital. "We are grateful to our new and existing investors for the commitment to our bold vision of creating the industry's first fully programmable epigenetic medicines," Mahesh Karande, Omega Therapeutics President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.